Fresenius SE & Co. KGaA

Equities

FRE

DE0005785604

Healthcare Facilities & Services

Real-time Estimate Tradegate Other stock markets 05:35:53 2024-04-23 am EDT			5-day change	1st Jan Change
27.68 ^EUR	+1.08%		+3.80%	-1.60%

11:13am	FRESENIUS SE : Goldman Sachs sticks Neutral	ZD
Apr. 22	European Equities Close Higher in Monday Trading; EC Probes TikTok Over Possible DSA Violations	MT

Jefferies raises target for Fresenius SE to 38 euros - 'Buy'.

June 02, 2023 at 05:35 am EDT

NEW YORK (dpa-AFX) - The analyst firm Jefferies raised its price target for Fresenius from 33 to 38 euros and left its rating at "buy". Analyst James Vane-Tempest raised his earnings estimates (EPS) for the medical group after the capital markets day on the Kabi drug division and the outlook upgrade. According to a study available on Friday on the medium-term corporate targets, he still sees room for improvement and points to uncertainties in important projects./gl/edh

Publication of the original study: 01.06.2023 / 04:46 / ET First disclosure of the original study: 01.06.2023 / 19:00 / ET

-----------------------

dpa-AFX Broker - the Trader News from dpa-AFX

-----------------------

Go to the original article.
Legal disclaimer

Latest news about Fresenius SE & Co. KGaA

FRESENIUS SE : Goldman Sachs sticks Neutral	05:13am	ZD
European Equities Close Higher in Monday Trading; EC Probes TikTok Over Possible DSA Violations	Apr. 22	MT
European Equities Traded in the US as American Depositary Receipts Rebound in Monday Trading	Apr. 22	MT
FRESENIUS SE : Receives a Buy rating from Jefferies	Apr. 22	ZD
Barclays reads 'Overweight' for Fresenius SE - Target 35 Euro	Apr. 22	DP
FRESENIUS SE : Barclays reiterates its Buy rating	Apr. 22	ZD
FRESENIUS SE : Berenberg keeps its Buy rating	Apr. 22	ZD
Positive trend of FMC and Fresenius continues	Apr. 22	DP
FRESENIUS SE : Gets a Neutral rating from JP Morgan	Apr. 18	ZD
Lauterbach wants to press ahead with hospital reform despite differences	Apr. 17	DP
State report warns of risks in hospital reform	Apr. 17	DP
FRESENIUS SE : Deutsche Bank maintains a Buy rating	Apr. 17	ZD
Warnings against cutbacks in hospital reform	Apr. 17	DP
Federal and state governments to discuss hospital reform again	Apr. 17	DP
FRESENIUS SE : Gets a Buy rating from Deutsche Bank	Apr. 16	ZD
STOXX 600 nears six-week low on geopolitical jitters; Ericsson shines	Apr. 16	RE
Fresenius at a two-month high - Tyenne launch and fantasy figures	Apr. 16	DP
Fresenius at two-month high - Tyenne launch a milestone	Apr. 16	DP
European Equities Traded in the US as American Depositary Receipts Start Week Higher in Monday Trading	Apr. 15	MT
Cannabis law and clinic atlas in the Bundesrat	Mar. 22	DP
European Equities Traded in the US as American Depositary Receipts Rise in Thursday Trading	Mar. 21	MT
Criticism of hospital reform: 'Redistribution from the bottom to the top'	Mar. 20	DP
European Equities Traded in the US as American Depositary Receipts Flat in Tuesday Trading	Mar. 19	MT
Formycon, Fresenius Kabi Sign Settlement Deal with Johnson & Johnson for Ustekinumab Biosimilar	Mar. 18	MT
Fresenius Settles With Johnson & Johnson to Market Stelara Alternative	Mar. 18	DJ

Chart Fresenius SE & Co. KGaA

Duration

Period

More charts

Company Profile

Fresenius SE & Co. KGaA specializes in designing, producing, and selling medical drugs, equipment, and devices used in clinical hospitalization and at home. Net sales break down by activity as follows: - dialysis treatment (46.9%; Fresenius Medical Care): sales of equipment for hemodialysis, pediatric dialysis, peritoneal dialysis, dialysis services, etc.; - hospital administration and engineering (34.1%; Fresenius Vamed and Fresenius Helios): management of technical facilities and medical equipment, hospital management, design and production of medical equipment for the pharmaceutical sector, etc.; - perfusion and clinical nutrition (19%; Fresenius Kabi): sales of parenteral and oral nutrition products, perfusion and vascular filling equipment, transfusion materials, generic injectable products, home medical assistance services in the areas of perfusion, nutrition, and oxygen therapy, etc. Net sales are distributed geographically as follows: Europe (43.8%), North America (39.4%), Asia/Pacific (10.1%), Latin America (5.4%) and Africa (1.3%).

Sector

Healthcare Facilities & Services

Calendar

2024-05-07 - Q1 2024 Earnings Call

Related indices

STOXX EUROPE 600 (EUR) , DAX

More about the company

Income Statement Evolution

More financial data

Analysis / Opinion

FRESENIUS : A good ending does not allow for extreme optimism in 2024

February 22, 2024 at 07:42 am EST

More Strategies

Ratings for Fresenius SE & Co. KGaA

Trading Rating

Investor Rating

ESG Refinitiv

A-

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

27.38 EUR

Average target price

36.22 EUR

Spread / Average Target

+32.28%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Healthcare Facilities & Services

	1st Jan change	Capi.
FRESENIUS SE & CO. KGAA	-1.60%	16.41B
CVS HEALTH CORPORATION	-11.82%	87.77B
HCA HEALTHCARE, INC.	+14.64%	82.08B
DR. SULAIMAN AL HABIB MEDICAL SERVICES GROUP COMPANY	+13.31%	30.03B
LABORATORY CORPORATION OF AMERICA HOLDINGS	-10.66%	17.08B
QUEST DIAGNOSTICS INCORPORATED	-5.65%	14.45B
EUROFINS SCIENTIFIC SE	+3.87%	12.37B
PURE HEALTH HOLDING	-31.75%	11.89B
FRESENIUS MEDICAL CARE AG	+4.40%	12.17B
DAVITA INC.	+26.50%	11.62B

Other Healthcare Facilities & Services